Therapy Areas: Respiratory
CStone doses first cancer patient with anti-CTLA-4 antibody CS1002 as part of its Phase I study in Australia
4 May 2018 -

Biopharmaceutical company CStone Pharmaceuticals (Suzhou) Co Ltd reported on Thursday the start of treatment of the first cancer patient with CS1002 under a Phase I clinical trial in Australia.

CS1002 is the company's investigational drug targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and also the first drug candidate that has entered clinical trials outside of China. CS1002 is an immunoglobulin G1 (IgG1), fully-human monoclonal antibody against CTLA-4.

The company said the CTLA-4 pathway takes effect during the early stage of immune response prior to the PD-1 checkpoint, occurring in the lymph nodes when CTLA-4 on activated T cells binds to its ligands B7-1 (CD80) or B7-2 (CD86) on tumor cells.A blockade of immune checkpoints using antibody drugs has been shown to promote T cell activation and proliferation, as well as stimulate the generation of memory T cells leading to durable anti-tumor response.

In conjunction, the company owns all global rights to CS1002 and intends to develop for the treatment of melanoma, non-small cell lung cancer, renal carcinoma as well as other solid tumors.

This Phase I study is being led by Professor Dusan Kotasek of the Ashford Cancer Centre Research and will assess CS1002's safety, tolerability, pharmacokinetics and initial efficacy in patients with advanced solid tumors.



Related Headlines